Hillstream Biopharma (NASDAQ:CNTN) Director Gary Stetz Sells 12,500 Shares

Hillstream Biopharma Inc. (NASDAQ:CNTN) Director Gary Stetz sold 12,500 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $3.47, for a total value of $43,375.00. Following the completion of the transaction, the director directly owned 134,175 shares in the company, valued at $465,587.25. This trade represents a 8.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Hillstream Biopharma Price Performance

Shares of NASDAQ CNTN traded down $0.06 on Wednesday, hitting $3.23. The company had a trading volume of 550,879 shares, compared to its average volume of 756,064. Hillstream Biopharma Inc. has a 12-month low of $1.08 and a 12-month high of $9.08. The firm has a market cap of $225.49 million, a price-to-earnings ratio of -2.81 and a beta of 1.44. The company has a 50 day moving average price of $3.33.

Hillstream Biopharma (NASDAQ:CNTN) last announced its earnings results on Wednesday, May 13th. The company reported ($0.23) EPS for the quarter.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of Hillstream Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings cut shares of Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 15th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.